bucindolol

出典: meddic



Wikipedia preview

出典(authority):フリー百科事典『ウィキペディア(Wikipedia)』「2015/05/16 23:43:54」(JST)

wiki en

[Wiki en表示]

UpToDate Contents

全文を閲覧するには購読必要です。 To read the full text you will need to subscribe.

英文文献

  • Cardiovascular pharmacogenomics: expectations and practical benefits.
  • Turner RM, Pirmohamed M.Author information 1] The Wolfson Centre for Personalised Medicine, Department of Molecular and Clinical Pharmacology, Institute of Translational Medicine, University of Liverpool, Liverpool, UK [2] Clinical Pharmacology, The Royal Liverpool University Hospital, Liverpool, UK.AbstractCardiovascular disease is a leading cause of morbidity and mortality worldwide. Pharmacogenomics is the study of genetic determinants of interindividual variation in drug response and aims to facilitate personalized medicine, through genotype-informed drug and dose selection, to maximize drug efficacy and/or minimize adverse drug reactions. Despite high expectations, no cardiovascular pharmacogenomic association is currently in widespread clinical practice; evidential, logistical, financial, and knowledge implementation barriers exist. Nevertheless, VKORC1, CYP2C9, and CYP4F2 variants have been associated with warfarin dose requirements, and CYP2C19 variants have been associated with perturbed antiplatelet response to clopidogrel. However, at present, controversy exists over the clinical utility of these genetic associations. There is an increased risk of simvastatin-induced muscle toxicity in SLCO1B1*5 carriers, ADRB1 and ADRA2C polymorphisms are associated with differential response to bucindolol, and rare congenital arrhythmia gene variants have been identified in drug-induced torsade de pointes. Practical benefits are still anticipated, but much work remains.
  • Clinical pharmacology and therapeutics.Clin Pharmacol Ther.2014 Mar;95(3):281-93. doi: 10.1038/clpt.2013.234. Epub 2013 Dec 9.
  • Cardiovascular disease is a leading cause of morbidity and mortality worldwide. Pharmacogenomics is the study of genetic determinants of interindividual variation in drug response and aims to facilitate personalized medicine, through genotype-informed drug and dose selection, to maximize drug effica
  • PMID 24322971
  • β1- and α2C-adrenergic receptor polymorphisms and the antiarrhythmic effect of bucindolol in heart failure with reduced ejection fraction.
  • Lymperopoulos A1, Negussie S, Walklett K.
  • Pharmacogenomics.Pharmacogenomics.2013 Oct;14(13):1545-9. doi: 10.2217/pgs.13.137.
  • PMID 24088125
  • Prevention of Atrial Fibrillation by Bucindolol Is Dependent on the Beta1389 Arg/Gly Adrenergic Receptor Polymorphism.
  • Aleong RG1, Sauer WH, Davis G, Murphy GA, Port JD, Anand IS, Fiuzat M, O'Connor CM, Abraham WT, Liggett SB, Bristow MR.Author information 1Section of Cardiac Electrophysiology, University of Colorado Denver, Denver, Colorado.AbstractOBJECTIVES: This study assessed the impact of bucindolol, a beta-blocker/sympatholytic agent, on the development of atrial fibrillation (AF) in advanced chronic heart failure with reduced left ventricular ejection fraction (HFREF) patients enrolled in the BEST (Beta-Blocker Evaluation of Survival Trial).
  • JACC. Heart failure.JACC Heart Fail.2013 Aug 1;1(4):338-344.
  • OBJECTIVES: This study assessed the impact of bucindolol, a beta-blocker/sympatholytic agent, on the development of atrial fibrillation (AF) in advanced chronic heart failure with reduced left ventricular ejection fraction (HFREF) patients enrolled in the BEST (Beta-Blocker Evaluation of Survival Tr
  • PMID 24159564

和文文献

  • Partial agonist activity of bucindolol is dependent on the activation state of the human β_1-adrenergic receptor
  • Comparison of the beta blocker bucindolol in younger vs older patients with heart failure
  • Bucindolol exerts agonistic activity on the propranolol-insensitive state of β_1-adrenoceptors in human myocardium

関連リンク

Bucindolol is a non-selective beta blocker with additional weak alpha-blocking properties and some intrinsic sympathomimetic activity. It was under review by the FDA in the United States for the treatment of heart failure in 2009 .

関連画像

nejm200105313442202_f1.gifBucindolol.png BUCINDOLOL. BUCINDOLOL. LABETALOLBucindololBucindolol ), nebivolol (Bystolic), and bucindolol


★リンクテーブル★
リンク元ブシンドロール
拡張検索bucindolol hydrochloride

ブシンドロール」

  [★]

bucindololbucindolol hydrochloride
塩酸ブシンドロール


bucindolol hydrochloride」

  [★]

bucindolol




★コメント★

[メモ入力エリア]
※コメント5000文字まで
ニックネーム:
コメント:




表示
個人用ツール


  meddic.jp

リンク
連絡